-

Dexcom Announces Upcoming Virtual Conference Presentations

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences:

  • Brice Bobzien, Vice President, Finance will present on behalf of the company at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 5:00pm (EST).
  • Jereme Sylvain, Executive Vice President and Chief Financial Officer will present on behalf of the company at the Citi 2022 Healthcare Services, Medtech, Tools and HCIT Virtual Conference on Wednesday, February 23, 2022 at 10:15am (EST).

Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com/ and will be archived there for future reference.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

Contacts

DexCom, Inc.
Sean Christensen
Senior Director – Investor Relations and Corporate FP&A
investor-relations@dexcom.com
(858) 200-0200

Industry:

DexCom, Inc.

NASDAQ:DXCM
Release Versions
English

Contacts

DexCom, Inc.
Sean Christensen
Senior Director – Investor Relations and Corporate FP&A
investor-relations@dexcom.com
(858) 200-0200

More News From DexCom, Inc.

Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their glucose health and take steps in achieving their long-term health goals. The newest features will launch nationwide in the coming weeks. Last year, Dexcom introduced AI-driven Smart Food Logging in Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the United...

Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will hold a conference call to review the company's fourth quarter and fiscal year 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations webs...

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook...
Back to Newsroom